Current Report Filing (8-k)
10 Noviembre 2022 - 7:36AM
Edgar (US Regulatory)
0001473579
false
0001473579
2022-10-21
2022-10-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): October 21, 2022
NANOMIX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware |
|
000-54586 |
|
27-0801073 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
2121 Williams Street, San Leandro, CA 94577
(Address of principal executive offices)
(510) 428-5300
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Not applicable |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02 Unregistered Sales of Equity Securities
On October 21, 2022, Nanomix Corporation (the “Company”)
entered into a subscription agreement with Mike Wickham, Managing Director of Woodley Equipment Company Ltd. (“Woodley”) pursuant
to which he purchased 213,000 shares of the Company’s common stock (the “Shares”) for an aggregate purchase price of
$250,000. The transactions contemplated by the subscription agreement closed on October 25, 2022.
The Shares were not registered under the Securities
Act or the securities laws of any state, and were offered and sold in reliance on the exemption from registration afforded by Section
4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder and corresponding
provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. Woodley is an “accredited
investor” as such term is defined in Regulation D promulgated under the Securities Act. This Current Report shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration
or an applicable exemption from the registration requirements and certificates evidencing such shares contain a legend stating the same.
The foregoing description of the subscription
agreement described above does not purport to be a complete description of the rights and obligations of the parties thereunder and is
qualified in its entirety by reference to the full text of such agreement, a copy of which is attached hereto as Exhibits 10.1 and is
incorporated herein by reference.
Item 8.01 Other Events
On November 9, 2022, the Company issued a press
release announcing that it had entered into a veterinary distribution agreement for its eLab System with Woodley. Under the agreement,
Woodley will engage in development and distribution activities focused on the veterinary market for regions outside of the United States
including the existing portfolio of the eLab system and the S1 critical infection panel. A copy of the press release is attached as Exhibit
99.1 to this report and is incorporated by reference into this Item 8.01.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NANOMIX CORPORATION |
|
|
|
|
By: |
/s/ David Ludvigson |
|
Name: |
David Ludvigson |
|
Title: |
Chief Financial Officer |
|
|
|
Date: November 10, 2022 |
|
|
2
Nanomix (CE) (USOTC:NNMX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Nanomix (CE) (USOTC:NNMX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Nanomix Corporation (CE) (OTCMarkets): 0 recent articles
Más de Nanomix Corp Artículos de Noticias